NCT07400991Recruiting
Restrictive Versus Liberal Fluid Intake in Acute Decompensated Heart Failure
Restrictive Versus Liberal Fluid Intake in Acute Decompensated Heart Failure: a Randomized Trial
Source: ClinicalTrials.gov · Last updated 7 May 2026
Brief summary (registry, in English)
The aim of this clinical trial is to learn whether a thirst-driven, liberal fluid-intake strategy is comparable to a fluid-restriction strategy in patients hospitalized for acute decompensated heart failure (ADHF). The study will also assess the safety of the intervention and its effects on thirst and quality of life. Patients hospitalized with ADHF will be asked to follow either a thirst-driven fluid-intake strategy or a fluid-restriction strategy during their hospital stay and for one month after discharge.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 420 (estimated)
- First submitted
- 3 Feb 2026
- Start date
- 1 May 2026
- Primary completion date
- 1 May 2029
- Lead sponsor
- Gødstrup Hospital
- Diseases
- Heart failure
- NCT number
- NCT07400991
What you commit to
- Study type: Interventional
- Planned participants: 420
- From 1 May 2026 to the primary completion date, 1 May 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Requirement at admission for ICU-level care, or IV inotropic/vasopressor therapy for ADHF.
Other illness
- Any condition which would make participation unsafe or substantially affect protocol adherence, as judged by investigator.
Lab values
- Na+ \<125 mmol/L or Na+ \>145 mmol/L.
- End-stage chronic kidney disease on chronic dialysis or eGFR \<15 mL/min/1.73 m2
Who the study is looking for
- Age \>18 years
- Hospitalized for ADHF as the primary diagnosis, meeting both of the following:
- ≥1 documented symptom of new or worsening heart failure (dyspnea, fatigue, decreased exercise tolerance, or symptom of end-organ hypoperfusion).
- Objective evidence of ADHF, defined as either:
- ≥2 physical signs (edema, ascites, pulmonary rales/crackles, increased JVP, S3 gallop, rapid weight gain due to fluid retention), OR ii. ≥1 physical sign AND ≥1 laboratory finding indicative of ADHF (BNP \>500 ng/L or NT-proBNP \>2000 ng/L if sinus rhythm, or BNP \>750 ng/L or NT-proBNP \>3000 ng/L if atrial fibrillation, radiological/ultrasound evidence of pulmonary congestion, echocardiographic sign \[VCI \>2.1 cm, LVOT VTI \<15 cm, E/e' \>14, D-dominant pulmonary venous inflow pattern\], or invasive evidence \[CVP \>12 mmHg, PCWP \>18 mmHg, CI \<2.2 L/min/m2\]).
- Treatment with ≥40 mg IV furosemide (or equivalent)
- Enrolment within 24 hours of admission
- Ability to provide informed consent
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Department of Cardiology, Gødstrup Hospital Coordinator of this site? Confirm its status | Herning | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.